Dynavax (DVAX) Mentioned Cautiously by theStreet's Adam Feuerstein

October 4, 2016 10:55 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Dynavax (NASDAQ: DVAX) was mentioned cautiously in an article by theStreet's Adam Feuerstein. The report said FDA precedent suggests its Hep B vaccine faces high rejection risk.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Related Entities

Adam Feuerstein

Add Your Comment